Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.

Antiviral therapy - 1 Jan 2011

Charpentier Charlotte, Larrouy Lucile, Matheron Sophie, Damond Florence, Delelis Olivier, Mouscadet Jean-François, Campa Pauline, Chêne Geneviève, Brun-Vézinet Françoise, Descamps Diane

Abstract excerpt

BACKGROUND: Little is known in HIV-2 infection about the kinetics of disappearance of raltegravir (RAL)-resistant virus after RAL withdrawal. METHODS: RAL was interrupted in four highly antiretroviral-experienced HIV-2-infected patients exhibiting a virological failure when receiving RAL. Integrase gene was sequenced from plasma samples collected at the time of RAL failure and at further time points following RAL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV-2
Share to HIV Integrase

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Integrase Inhibitors

Share to HIV Reverse Transcriptase

Share to Pyrrolidinones

Share to Raltegravir Potassium

Share to Salvage Therapy

Share to Viral Load

Source

Identifiers

PMID: 21900727
DOI: 10.3851/IMP1826

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.PMID 21900727Read ↗

The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy.Semantic proximity Read ↗

Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral TherapySemantic proximity Read ↗

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.Semantic proximity Read ↗

Stable HIV-1 integrase diversity during initial HIV-1 RNA decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy.Semantic proximity Read ↗

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.Semantic proximity Read ↗

Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.Semantic proximity Read ↗

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.Semantic proximity Read ↗

Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy.Semantic proximity Read ↗

Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.Semantic proximity Read ↗

Reversal periods and patterns from drug-resistant to wild-type HIV type 1 after cessation of anti-HIV therapy.Semantic proximity Read ↗

Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.Semantic proximity Read ↗

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.